Research Catalog
High-purity, structurally verified peptide sequences for advanced laboratory and pre-clinical applications.
High-purity, structurally verified peptide sequences for advanced laboratory and pre-clinical applications.
For in vitro laboratory research use only. Not for human or veterinary use. Not evaluated by the FDA. Must be 21+ to purchase.

CJC-1295 without DAC (Drug Affinity Complex), also known as Modified GRF (1-29), is a synthetic analog of growth hormone-releasing hormone (GHRH). With the molecular formula C₁₅₂H₂₅₂N₄₄O₄₂ and a molecular weight of 3367.9 g/mol (CAS: 863288-34-0), this peptide represents the first 29 amino acids of GHRH with modifications at positions 2 (D-Ala), 8 (Ala), 15 (Gln), 16 (Leu), 23 (Tyr), 24 (Gln), and 28 (Ser).
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Ala-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-SerJette et al. (2005) characterized the modified GRF analog's binding affinity to GHRH receptors and its half-life modifications (PMID: 15775957).
PMID: 15775957VERIFY PMIDRoh et al. (2006) investigated the structure-activity relationships of modified GRF peptides on pituitary cells (PMID: 16452336).
PMID: 16452336VERIFY PMIDCJC-1295 NO DAC binds to GHRH receptors on pituitary somatotrophs, activating adenylate cyclase and increasing intracellular cAMP in cell culture (PMID: 15775957).
The peptide triggers intracellular calcium release and growth hormone secretion through GHRH receptor activation (PMID: 16452336).
All compounds are sold strictly for laboratory research use. Not for human or animal consumption. These products are not drugs, supplements, or food. Statements have not been evaluated by the FDA. Must be 21+ to purchase. This compound is intended exclusively for in vitro laboratory research. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.
Scientific Context